Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $216.35 million. Neogen's ROE for the same period is 11.22%.

The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $188.77 million. Abaxis had $85.89 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO) is $188.69 million. Meridian Bioscience's operating margin for the same period is 30.38%.

The trailing-twelve-month revenue at Quidel (NASDAQ: QDEL) is $177.66 million. Quidel's profit margin for the same period is 8.44%.